Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer
Authors
Keywords
-
Journal
Cancer Medicine
Volume 6, Issue 10, Pages 2263-2270
Publisher
Wiley
Online
2017-08-23
DOI
10.1002/cam4.1164
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Stereotactic Body Radiation Therapy: A New Standard Option for Pancreatic Cancer?
- (2017) Joseph M. Herman et al. Journal of the National Comprehensive Cancer Network
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions
- (2016) Sten Myrehaug et al. Expert Review of Anticancer Therapy
- Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial
- (2016) Xiaofei Zhu et al. BMJ Open
- Pancreatic cancer surgery in elderly patients: Balancing between short-term harm and long-term benefit. A population-based study in the Netherlands
- (2015) Lydia G. M. van der Geest et al. ACTA ONCOLOGICA
- Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer
- (2015) Jang-Chun Lin et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Resected pancreatic cancer outcomes in the elderly
- (2015) Jessica M. Frakes et al. Journal of Geriatric Oncology
- Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force
- (2014) I. H. Kunkler et al. ANNALS OF ONCOLOGY
- Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma
- (2014) Joseph M. Herman et al. CANCER
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
- (2013) Helmut Oettle et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Stereotactic body radiotherapy in the treatment of Pancreatic Adenocarcinoma in elderly patients
- (2013) Carolyn H Kim et al. Radiation Oncology
- Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III Trial
- (2011) William F. Regine et al. ANNALS OF SURGICAL ONCOLOGY
- Adjuvant Chemoradiation Therapy After Pancreaticoduodenectomy in Elderly Patients With Pancreatic Adenocarcinoma
- (2010) David P. Horowitz et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Stereotactic body radiation therapy: The report of AAPM Task Group 101
- (2010) Stanley H. Benedict et al. MEDICAL PHYSICS
- Outcomes and Tolerability of Chemoradiation Therapy for Pancreatic Cancer Patients Aged 75 Years or Older
- (2009) David T. Miyamoto et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Analysis of Fluorouracil-Based Adjuvant Chemotherapy and Radiation After Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreas: Results of a Large, Prospectively Collected Database at the Johns Hopkins Hospital
- (2008) Joseph M. Herman et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started